Literature DB >> 10747265

An open comparative study of dispersible piroxicam versus soluble acetylsalicylic acid for the treatment of osteoarticular painful attack during sickle cell crisis.

F U Eke1, A Obamyonyi, N N Eke, E A Oyewo.   

Abstract

We compared the efficacy and tolerability of oral piroxicam 1 mg/kg/day with soluble aspirin given at 100 mg/kg/day taken four-hourly in 58 patients with sickle cell anaemia and severe ostcoarticular painful attacks requiring hospitalization in a randomized, paralleled study. Main investigational criteria were pain relief, limitation of movement, fever, and insomnia or agitation. Both groups were well-matched at the commencement of therapy but most patients on piroxicam showed remarkable and significant pain relief and improvement in other parameters within 24 h. Unwanted effects were absent in the piroxicam-treated group whereas those treated with aspirin experienced nausea and vomiting. There were no significant changes in liver function tests with both forms of treatment. Oral piroxicam is an effective and safe treatment in the management of the osteoarticular painful crisis in sickle cell anaemia. It might prevent the use of parenteral analgesics and hospitalization and reduce the loss of school hours in patients who are being treated for bone pain crises that characterize sickle cell anaemia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10747265     DOI: 10.1046/j.1365-3156.2000.00507.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  6 in total

1.  Role of the coagulation system in the pathogenesis of sickle cell disease.

Authors:  Md Nasimuzzaman; Punam Malik
Journal:  Blood Adv       Date:  2019-10-22

2.  Use of anti-inflammatory analgesics in sickle-cell disease.

Authors:  J Han; S L Saraf; J P Lash; V R Gordeuk
Journal:  J Clin Pharm Ther       Date:  2017-07-10       Impact factor: 2.512

3.  Effects of pyrimethamine versus proguanil in malarial chemoprophylaxis in children with sickle cell disease: a randomized, placebo-controlled, open-label study.

Authors:  Felicia U Eke; Ifeoma Anochie
Journal:  Curr Ther Res Clin Exp       Date:  2003-09

Review 4.  Therapeutic strategies for sickle cell disease: towards a multi-agent approach.

Authors:  Marilyn J Telen; Punam Malik; Gregory M Vercellotti
Journal:  Nat Rev Drug Discov       Date:  2019-02       Impact factor: 84.694

5.  Treatment for avascular necrosis of bone in people with sickle cell disease.

Authors:  Arturo J Martí-Carvajal; Ivan Solà; Luis H Agreda-Pérez
Journal:  Cochrane Database Syst Rev       Date:  2019-12-05

6.  Evidence-based interventions implemented in low-and middle-income countries for sickle cell disease management: A systematic review of randomized controlled trials.

Authors:  Joyce Gyamfi; Temitope Ojo; Sabrina Epou; Amy Diawara; Lotanna Dike; Deborah Adenikinju; Scholastica Enechukwu; Dorice Vieira; Obiageli Nnodu; Gbenga Ogedegbe; Emmanuel Peprah
Journal:  PLoS One       Date:  2021-02-17       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.